ArticleACS omega2025
DFO-Loaded Tussah Silk Nanofibrous Membranes for Guided Bone Regeneration.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biopolymer nanofibrous membranes have gained considerable attention as advanced biomaterial scaffolds for guided bone regeneration owing to their remarkable structural and functional characteristics. In this study, we developed a novel composite membrane by incorporating deferoxamine (DFO) into tussah silk nanofibrous (Tsn) membranes to synergistically enhance angiogenic and osteogenic capabilities. The physically sheared Tsn membranes predominantly exhibited β-sheet conformations, confirming the preservation of silk's natural secondary structure. Comparative analysis between pristine Tsn and DFO-loaded (DFO-Tsn) membranes revealed that drug incorporation resulted in modest reductions in mechanical parameters, including breaking stress, breaking strain, and Young's modulus. In vitro evaluations demonstrated a time-dependent increase in cell proliferation within the DFO-loaded group, suggesting that the composite membrane maintained excellent biocompatibility. Most notably, when implanted in a rat cranial defect model, the DFO-Tsn group showed substantially enhanced bone regeneration compared to Tsn controls, as evidenced by comprehensive micro-CT analysis and histomorphometric evaluation. These findings collectively demonstrate that DFO-loaded Tsn membranes show great potential for use in bone tissue regeneration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.